Immix Biopharma Inc. is a biopharmaceutical company pioneering Tissue Specific Therapeutics (TM) targeting oncology and immuno-dysregulated diseases. Immix Biopharma Inc. is based in LOS ANGELES.
Revenue (Most Recent Fiscal Year) | -- |
Net Income (Most Recent Fiscal Year) | $-15.43M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.07 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -- |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -101.56% |
Return on Assets (Trailing 12 Months) | -86.70% |
Current Ratio (Most Recent Fiscal Quarter) | 5.32 |
Quick Ratio (Most Recent Fiscal Quarter) | 5.32 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $0.81 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.24 |
Earnings per Share (Most Recent Fiscal Year) | $-0.89 |
Diluted Earnings per Share (Trailing 12 Months) | $-0.89 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 26.40M |
Free Float | 11.64M |
Market Capitalization | $65.99M |
Average Volume (Last 20 Days) | 0.15M |
Beta (Past 60 Months) | 0.05 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 55.90% |
Percentage Held By Institutions (Latest 13F Reports) | 11.26% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |